| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1988 | 2018 |
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823, 2017 | 1655 | 2017 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ... Science translational medicine 8 (346), 346ra92-346ra92, 2016 | 1512 | 2016 |
| Investigation of the safety of irreversible electroporation in humans KR Thomson, W Cheung, SJ Ellis, D Federman, H Kavnoudias, ... Journal of Vascular and Interventional Radiology 22 (5), 611-621, 2011 | 578 | 2011 |
| Effect of physical activity and body size on survival after diagnosis with colorectal cancer AMM Haydon, RJ MacInnis, DR English, GG Giles Gut 55 (1), 62-67, 2006 | 496 | 2006 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 438 | 2022 |
| Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma R Dummer, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 383 (12), 1139-1148, 2020 | 408 | 2020 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 397 | 2020 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 356 | 2021 |
| Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, ... Gut 68 (4), 663-671, 2019 | 345 | 2019 |
| Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III … A Hauschild, R Dummer, D Schadendorf, M Santinami, V Atkinson, ... Journal of Clinical Oncology 36 (35), 3441-3449, 2018 | 299 | 2018 |
| Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... Journal of Clinical Oncology 38 (33), 3925-3936, 2020 | 286 | 2020 |
| Red meat, chicken, and fish consumption and risk of colorectal cancer DR English, RJ MacInnis, AM Hodge, JL Hopper, AM Haydon, GG Giles Cancer Epidemiology Biomarkers & Prevention 13 (9), 1509-1514, 2004 | 266 | 2004 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 247 | 2018 |
| Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype MD Walsh, M Clendenning, E Williamson, SA Pearson, RJ Walters, ... Modern pathology 26 (12), 1642-1656, 2013 | 232 | 2013 |
| 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial TJ Iveson, RS Kerr, MP Saunders, J Cassidy, NH Hollander, J Tabernero, ... The Lancet Oncology 19 (4), 562-578, 2018 | 210 | 2018 |
| Emerging pathways in colorectal-cancer development AMM Haydon, JR Jass The lancet oncology 3 (2), 83-88, 2002 | 209 | 2002 |
| Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer B Lee, L Lipton, J Cohen, J Tie, AA Javed, L Li, D Goldstein, M Burge, ... Annals of Oncology 30 (9), 1472-1478, 2019 | 197 | 2019 |
| Body size and composition and colon cancer risk in men RJ MacInnis, DR English, JL Hopper, AM Haydon, DM Gertig, GG Giles Cancer Epidemiology Biomarkers & Prevention 13 (4), 553-559, 2004 | 180 | 2004 |
| Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma JR Patrinely, R Johnson, AR Lawless, P Bhave, A Sawyers, M Dimitrova, ... JAMA oncology 7 (5), 744-748, 2021 | 174 | 2021 |
